With continuous sales growth in the domestic market and further strengthening of its position in Macedonia, “Replek AD Skopje” achieved total sales revenues in the pharmaceutical segment of 13.9 million euros in the first six months of 2026. Revenues generated in the domestic market increased by 24% compared with the same period last year, reaching sales of 4.8 million euros, which is the strongest driver of results in the first half of this year.
Of the total sales revenue in the first half of 2026, 9.1 million euros were generated in export markets, while the share of the domestic market increased to 35%, confirming the growing role of the domestic segment in the company’s revenue structure.
“The continued growth in the domestic market is a clear confirmation that our portfolio development strategy, investments in new products, and commitment to patients and partners in the country are delivering concrete results. We are particularly encouraged by the fact that the growth in the domestic market intensified during the second quarter, and this trend continues, which represents a strong foundation for the company’s further development. At the same time, we remain fully committed to our international strategy and to further strengthening our presence in foreign markets,” said Dushan Pecovski, CEO of Replek.
The growth in the domestic market is a result of the company’s strengthened market position, the positive reception of the new products launched during the past year, and the continued growth of key product lines. These results reaffirm the confidence that patients, healthcare professionals, and business partners have in Replek’s products, as well as the successful implementation of the commercial strategy in the domestic market.
During the first half of the year, sales in export markets followed a different dynamic, primarily due to changes in the delivery schedules of certain distribution partners, which led to the postponement of some of the planned shipments. Demand across key markets remains stable, orders are being fulfilled, and the company continues to implement the agreed activities in accordance with the adjusted delivery schedule.
In the context of a changing global business environment, Replek remains focused on flexible export management and further strengthening its international position. In addition, the company completed its first export to the UK market during the first half of the year, which represents a significant strategic milestone and confirmation of Replek’s ability to successfully operate in highly regulated pharmaceutical markets.
Looking ahead, “Replek” will continue to implement its long-term growth strategy through the development of new products, expansion into international markets, new regulatory approvals, and investments in manufacturing modernisation. The construction of a new manufacturing facility for semi-solid and liquid pharmaceutical forms is currently underway, as one of the most significant investments of the company in this period, which will further strengthen production capacities and competitiveness in the domestic and foreign markets. The company remains committed to creating sustainable growth, continuous improvement of operational efficiency, and creating long-term value for its shareholders, partners, and patients.